Dicerna
is a Massachusetts-based biotechnology company that develops and commercializes RNAi therapies for the treatment of cardiometabolic and complement-mediated diseases... Read moreDicerna
is a Massachusetts-based biotechnology company that develops and commercializes RNAi therapies for the treatment of cardiometabolic and complement-mediated diseases... Read more
2006
PrivateAcquired by Novo Nordisk A/S
News
Nov 18, 2023
Pharamceutical Technology
Dicerna: DCR-STAT3 by Dicerna Pharmaceuticals for Solid Tumor: Likelihood of Approval
Nov 11, 2022
REBusinessOnline
Dicerna: Dicerna Pharmaceuticals Signs 107,238 SF Life Sciences Lease Expansion in Lexington, Massachusetts
Jan 02, 2022
Citybizlist
Dicerna: Novo Nordisk Completes Dicerna Pharmaceuticals Acquisition
Dec 29, 2021
Post Online Media
Dicerna: Novo Nordisk completes acquisition of Dicerna Pharmaceuticals
Dec 26, 2021
Markets Insider
Dicerna: Dicerna - Novo Nordisk Deal Receives U.S. Antitrust Approval
Dec 25, 2021
MarketScreener
Dicerna: Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna
Dec 14, 2021
centralcharts
Press Release: Dicerna : DICERNA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dicerna Pharmaceuticals, Inc. - DRNA
Dec 08, 2021
Seeking Alpha
Dicerna: Dicerna Pharma ticks lower after Novo Nordisk withdraws antitrust filing, will refile
Nov 22, 2021
MarketScreener
Dicerna: SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Dicerna Pharmaceuticals, Inc. - DRNA
Nov 22, 2021
BioPharma-Reporter
Dicerna: Novo Nordisk to acquire Dicerna Pharmaceuticals
